Polycystic kidney disease in patients on the renal transplant waiting list: Trends in hematocrit and survival

BMC Nephrology

Volumn 3, Issue , 2002, Pages 1-6

  Abbott, Kevin C ^a,b   Agodoa, Lawrence Y ^c  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Age; Albumin; Caucasian; Complications; Dialysis; Dysrythmias; EPO; Female; Frequency; Hemoglobin; Mortality; Peritoneal dialysis; Polycystic kidney disease; Transplantation; USRDS; Weight

Indexed keywords

HEMOGLOBIN;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GRAFT SURVIVAL; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HUMAN; KIDNEY FAILURE; KIDNEY GRAFT; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; LINEAR REGRESSION ANALYSIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; HOSPITAL ADMISSION; METABOLISM; MIDDLE AGED; MORTALITY; PERITONEAL DIALYSIS; REGISTER; REGRESSION ANALYSIS; RENAL REPLACEMENT THERAPY; STATISTICS; SURVIVAL RATE; UNITED STATES;

FEMALE; HEMATOCRIT; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; POLYCYSTIC KIDNEY DISEASES; REGISTRIES; REGRESSION ANALYSIS; RENAL DIALYSIS; SURVIVAL RATE; UNITED STATES; WAITING LISTS;

EID: 3342982932     PISSN: 14712369     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-3-7     Document Type: Article

References (12)

1. Perrone RD, Ruthazer R, Terrin NC: Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: contribution of extrarenal complications to mortality. Am J Kidney Dis 2001, 38:777-84
2. Fourtounas C, Panteris V, Valis D: Survival after end-stage renal disease in autosomal dominant polycystic kidney disease. Am J Kidney Dis 2002, 39:660
3. Abbott KC, Agodoa LY: Polycystic kidney disease at end-stage renal disease in the United States: patient characteristics and survival. Clin Nephrol 2002, 57:208-14
4. Longenecker JC, Coresh J, Klag MJ, Levey AS, Martin AA, Fink NE, Powe NR: Validation of comorbid conditions on the end-stage renal disease medical evidence report: the CHOICE study. Choices for Healthy Outcomes in Caring for ESRD. J Am Soc Nephrol 2000, 11:520-529
5. Chandra M, Miller ME, Garcia JF, Mossey RT, McVicar M: Serum immunoreactive erythropoietin levels in patients with polycystic kidney disease as compared with other hemodialysis patients. Nephron 1985, 39(1):26-9
6. Rotellar C, Gelfand MC: Polycystic kidneys do maintain good endocrine function. Med Hypotheses 1989, 30:61-4
7. Linblad AS, Nolph KD: Hematocrit values in the CAPD/CCPD population: a report of the National CAPD Registry. Perit Dial Int 1990, 10:275-8
8. Glicklich D, Kutcher R, Rosenblatt R, Barth RH: Time-related increase in hematocrit on chronic hemodialysis: uncertain role of renal cysts. Am J Kidney Dis 1990, 15:46-54
9. Hadimeri H, Johansson AC, Haraldsson B, Nyberg G: CAPD in patients with autosomal dominant polycystic kidney disease. Perit Dial Int 1998, 18:429-32
10. Locatelli AJ, Marcos GM, Gomez MG, Alvarez SA, DeBenedetti LC: Comparing peritonitis in continuous ambulatory peritoneal dialysis patients versus automated peritoneal dialysis patients. Adv Perit Dial 1999, 15:193-6
11. Lieske JC, Toback FG: Autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1993, 3:1442-50
12. Brady HR, Wilcox CS, eds: Renal Cystic Diseases in Therapy in Nephrology and Hypertension (Edited by: Brenner BM Editor in Chief) W.B. Saunders Company, Philadelphia 367-374